William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on VRDN stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors tied to the growing strength and de-risking of Viridian Therapeutics’ lead program, veligrotug. The FDA’s acceptance of the biologics license application, along with granting priority review and setting a June 30, 2026 PDUFA date, signals regulatory confidence and accelerates the potential path to market. He views the early BLA acceptance as evidence of solid execution by management and a constructive working relationship with the agency, which together reduce regulatory uncertainty around the asset.
In addition, his positive stance reflects the robust clinical profile demonstrated in the large Phase III THRIVE and THRIVE 2 trials, which showed strong efficacy in both active and chronic thyroid eye disease, including meaningful improvements in diplopia. The data suggest veligrotug could offer a more attractive treatment option versus the current standard, with fewer infusions over a shorter overall treatment window and reduced infusion time per visit, thereby lowering patient burden. These clinical and convenience advantages, coupled with the potential for meaningful commercial uptake following a mid-2026 launch, underpin his conviction that Viridian’s shares remain undervalued relative to the company’s future prospects, justifying a Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.